Personalized & precision medicine approaches for the treatment of cardiovascular disease
Isabela Garcia Pleijlar Abbreviations CAD, Coronary Artery Disease; CHD, Congenital Heart Disease; CVD, Cardiovascular Disease; DNA, Deoxyribonucleic acid; ESCs, Embryonic Stem Cells; FDA, Food and Drug Administration; FRESH, Freeform Reversible Embedding of Suspended Hydrogels; hERG, the human ether-a-go-go related gene; hESC-CM, human Embryonic Stem Cell-derived Cardiomyocytes; HGF, Hepatocyte Growth Factor; hiPSC-CMs, human induced Pluripotent […]
Advanced Therapies Congress 2023
ExCeL centre, London, 14-15 March, 2023 On the 14th and 15th of March 2023, PMM team members Atiyeh Razavi, Isabela Garcia Pleijlar, and Clotilde Vazquez attended the Advanced Therapies Congress held at the London ExCeL. The Advanced Therapies Congress explored, defined, and attempted to tackle the main challenges currently being faced when it comes […]
Advanced Therapies Europe 2022
On the 31st August and 1st September, 2022, PMM volunteer and team member, Rithika Ganesh, attended the annual Advanced Therapies Europe Conference which was held at the Royal Lancaster hotel in London, United Kingdom. The Advanced Therapies Europe 2022 conference focused on exploring the commercialization of advanced therapy medicinal products (ATMPs), with talks […]
Advanced Therapies Congress, 24-25 May, 2022, ExCel, London
On the 24th of May, 2022, PMM team members, Xuanqi Song and Sam Jarada, attended the Advanced Therapies Congress held at the London ExCeL. The Advanced Therapies Congress explored, defined, and attempted to tackle the main challenges currently being faced when it comes to the development of patient access to advanced therapy medicinal products (ATMP). […]
Advanced Therapies Congress & Expo 2021
On the 5th of October, 2021, PMM team members Celeste Cohen, Shannon Hylton, and Aaron Logsdon attended the Advanced Therapies Congress held at the London ExCeL. The Advanced Therapies Congress explored, defined, and attempted to tackle the main challenges currently being faced when it comes to the development of patient access to advanced therapy medicinal products […]
Huntington’s disease: prevention and current innovations in treatment
Huntington’s disease: prevention and current innovations in treatment Jenny Chatzigerou Glossary Allele, Antibody, Autosomal, DNA, Gene, MicroRNA, mRNA, Neurodegenerative disorder, Neuron, Neuroleptic, Neurotransmitter, Nucleotide, Polymorphism, RNA Huntington’s disease (HD) is a genetic neurodegenerative disorder that was first described in 1872 by the physician George Huntington,1 in his seminal paper ‘On Chorea’. Huntington described the condition […]